Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Allan L KleinMassimo ImazioPaul CremerAntonio BrucatoAntonio AbbateFang FangAntonella InsalacoMartin LeWinterBasil S LewisDavid LinSushil A LuisStephen J NichollsArian PanoAlistair WheelerJohn F Paolininull nullPublished in: The New England journal of medicine (2020)
Among patients with recurrent pericarditis, rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo. (Funded by Kiniksa Pharmaceuticals; RHAPSODY ClinicalTrials.gov number, NCT03737110.).